X0306 4 2020-08-03 0 0001645460 Cue Biopharma, Inc. CUE 0001739130 Suri Anish C/O CUE BIOPHARMA, INC. 21 ERIE STREET CAMBRIDGE MA 02139 0 1 0 0 President and CSO Common Stock 2020-08-03 4 M 0 2000 8.26 A 36558 D Common Stock 2020-08-03 4 M 0 3800 6.42 A 40358 D Common Stock 2020-08-03 4 S 0 5800 20.01 D 34558 D Common Stock 2020-08-04 4 M 0 400 6.42 A 34958 D Common Stock 2020-08-04 4 S 0 400 20.14 D 34558 D Stock Option (right to buy) 8.26 2020-08-03 4 M 0 2000 0.00 D 2025-08-14 Common Stock 2000 18000 D Stock Option (right to buy) 6.42 2020-08-03 4 M 0 3800 0.00 D 2029-03-06 Common Stock 3800 146200 D Stock Option (right to buy) 6.42 2020-08-04 4 M 0 400 0.00 D 2029-03-06 Common Stock 400 145800 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.11 to $20.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. This stock option grant becomes exercisable in eight equal semi-annual installments beginning November 14, 2018. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. /s/ Anish Suri by Mark Busch, attorney-in-fact 2020-08-05